Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
184,457
clinical trials

Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cerritos, CA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Columbia, SC
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Doral, FL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Doylestown, PA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Glendale, CA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hudson, FL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
La Palma, CA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Mentor, OH
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Salisbury, NC
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Anaemia Clinical Trial
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling, Phase III
Updated: 12/31/1969
GSK Investigational Site
mi
from
Upland, CA
Click here to add this to my saved trials
Neoplasms Clinical Trial
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Status: Enrolling, Phase I, II
Updated: 12/31/1969
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
The Ohio State University Wexner Medical Center, James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10036
mi
from
Augusta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10014
mi
from
Charleston, SC
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10042
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10001
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
University of New Mexico Comprehensive Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Lions Eye Institute
mi
from
Aurora, CO
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Tower Hematology Oncology Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Utah Cancer Specialists
mi
from
Murray, UT
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
UC San Diego Medical Center - Hillcrest
mi
from
San Diego, CA
Click here to add this to my saved trials
Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Status: Enrolling, Phase III
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
Dana Farber Cancer Institute/Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
University of Texas Health Sciences Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Status: Enrolling, Phase II
Updated: 4/30/2018
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Utah Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
University of California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
UCSF Cardiovascular Care and Prevention Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Germantown, TN
Click here to add this to my saved trials
Oncology Clinical Trial
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Endocrinology, Ophthalmology Clinical Trial
Adaptive Optics for Ophthalmic Technologies
Status: Enrolling
Updated: 12/31/1969
Duke Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling, Phase III
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling, Phase III
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling, Phase III
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Clinical Trial
Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Clinical Trial
Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations
Status: Enrolling, Phase II
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Infantile-onset Spinal Muscular Atrophy (SMA) Clinical Trial
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Status: Enrolling
Updated: 12/1/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Status: Enrolling, Phase III
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Status: Enrolling, Phase III
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Status: Enrolling, Phase III
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Status: Enrolling, Phase III
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Status: Enrolling, Phase III
Updated: 12/31/1969
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Harold Alfond Center for Cancer Care
mi
from
Augusta, ME
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Flaget Memorial Hospital
mi
from
Bardstown, KY
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Ochsner Health Center-Summa
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Woman's Hospital
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Cleveland Clinic Cancer Center Beachwood
mi
from
Beachwood, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Dayton Physicians LLC-Miami Valley South
mi
from
Centerville, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KS
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Mount Sinai Hospital Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials